NASDAQ:CLLS

Cellectis News Headlines

$13.46
+0.18 (+1.36 %)
(As of 07/30/2021 11:32 AM ET)
Add
Compare
Today's Range
$13.32
$13.64
50-Day Range
$12.99
$16.35
52-Week Range
$12.62
$34.71
Volume3,949 shs
Average Volume325,578 shs
Market Capitalization$611.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Cellectis (NASDAQ CLLS) News Headlines Today

SourceHeadline
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT - GlobeNewswireCellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT - GlobeNewswire
globenewswire.com - July 29 at 5:33 PM
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CETCellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
finance.yahoo.com - July 29 at 5:33 PM
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDTCellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
finance.yahoo.com - July 29 at 5:33 PM
Metagenomi Appoints Simon Harnest as Chief Investment Officer - StreetInsider.comMetagenomi Appoints Simon Harnest as Chief Investment Officer - StreetInsider.com
streetinsider.com - July 29 at 7:32 AM
Metagenomi Appoints Simon Harnest as Chief Investment Officer - Yahoo FinanceMetagenomi Appoints Simon Harnest as Chief Investment Officer - Yahoo Finance
finance.yahoo.com - July 28 at 2:51 PM
Metagenomi Appoints Simon Harnest as Chief Investment Officer - Business WireMetagenomi Appoints Simon Harnest as Chief Investment Officer - Business Wire
businesswire.com - July 28 at 9:49 AM
Cellectis S.A. (NASDAQ:CLLS) Given Average Recommendation of "Buy" by BrokeragesCellectis S.A. (NASDAQ:CLLS) Given Average Recommendation of "Buy" by Brokerages
americanbankingnews.com - July 28 at 1:26 AM
Cellectis (NASDAQ:CLLS) Sets New 52-Week Low at $13.07Cellectis (NASDAQ:CLLS) Sets New 52-Week Low at $13.07
americanbankingnews.com - July 26 at 12:43 PM
Cellectis (NASDAQ:CLLS) Shares Gap Up to $13.85Cellectis (NASDAQ:CLLS) Shares Gap Up to $13.85
americanbankingnews.com - July 23 at 10:28 AM
Cellectis (NASDAQ:CLLS) Sets New 1-Year Low at $13.44Cellectis (NASDAQ:CLLS) Sets New 1-Year Low at $13.44
americanbankingnews.com - July 15 at 12:43 PM
Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential - Seeking AlphaCellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential - Seeking Alpha
seekingalpha.com - July 13 at 10:30 PM
Zacks: Brokerages Anticipate Cellectis S.A. (NASDAQ:CLLS) Will Post Quarterly Sales of $12.43 MillionZacks: Brokerages Anticipate Cellectis S.A. (NASDAQ:CLLS) Will Post Quarterly Sales of $12.43 Million
americanbankingnews.com - July 12 at 2:28 AM
Zacks: Brokerages Expect Cellectis S.A. (NASDAQ:CLLS) to Post -$0.75 EPSZacks: Brokerages Expect Cellectis S.A. (NASDAQ:CLLS) to Post -$0.75 EPS
americanbankingnews.com - July 10 at 3:16 PM
Cellectis (NASDAQ:CLLS) Sees Large Volume IncreaseCellectis (NASDAQ:CLLS) Sees Large Volume Increase
americanbankingnews.com - July 9 at 11:57 AM
2 “Strong Buy” Stocks Flirting With a Bottom - Nasdaq2 “Strong Buy” Stocks Flirting With a Bottom - Nasdaq
nasdaq.com - July 9 at 1:09 AM
2 “Strong Buy” Stocks  Flirting With a Bottom2 “Strong Buy” Stocks Flirting With a Bottom
finance.yahoo.com - July 8 at 8:09 PM
Cellectis (NASDAQ:CLLS) Reaches New 12-Month Low at $14.18Cellectis (NASDAQ:CLLS) Reaches New 12-Month Low at $14.18
americanbankingnews.com - July 7 at 11:54 AM
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century - NasdaqThe Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century - Nasdaq
nasdaq.com - July 3 at 9:57 AM
Allogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag - NasdaqAllogene (ALLO) Multiple Myeloma Candidate Gets Fast Track Tag - Nasdaq
nasdaq.com - July 1 at 7:38 PM
CRISPR: 4 Emerging Players - Seeking AlphaCRISPR: 4 Emerging Players - Seeking Alpha
seekingalpha.com - June 30 at 1:40 PM
Global Gene Therapy Markets Report 2021-2030: Antigen, Cytokine, Suicide Gene, Viral Vector, Non-Viral Vector, Oncological, Rare Diseases, Cardiovascular, Neurological Disorders, Infectious Diseases - Yahoo FinanceGlobal Gene Therapy Markets Report 2021-2030: Antigen, Cytokine, Suicide Gene, Viral Vector, Non-Viral Vector, Oncological, Rare Diseases, Cardiovascular, Neurological Disorders, Infectious Diseases - Yahoo Finance
finance.yahoo.com - June 25 at 7:47 AM
Gene Therapy Global Market Report 2021: COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com - Business WireGene Therapy Global Market Report 2021: COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com - Business Wire
businesswire.com - June 24 at 12:51 PM
Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside - Seeking AlphaCellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside - Seeking Alpha
seekingalpha.com - June 22 at 5:41 PM
Olivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer - StreetInsider.comOlivier Gouédard, PharmD, MBA joins Cytovia Therapeutics as Chief Operating Officer - StreetInsider.com
streetinsider.com - June 22 at 12:41 PM
William Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer - StreetInsider.comWilliam Sullivan, CPA, MBA joins Cytovia Therapeutics as Chief Financial Officer - StreetInsider.com
streetinsider.com - June 15 at 5:44 PM
Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors - Yahoo FinanceCellectis Unveils Four Additional Preclinical Candidates For Solid Tumors - Yahoo Finance
finance.yahoo.com - June 15 at 5:44 PM
Cellectis Unveils Four Additional Preclinical Candidates For Solid Tumors - BenzingaCellectis Unveils Four Additional Preclinical Candidates For Solid Tumors - Benzinga
benzinga.com - June 15 at 12:43 PM
Cellectis Unveils Four Additional Preclinical Candidates For Solid TumorsCellectis Unveils Four Additional Preclinical Candidates For Solid Tumors
finance.yahoo.com - June 15 at 12:43 PM
StrideBio Expands Leadership Team with Accomplished Industry Executives - StreetInsider.comStrideBio Expands Leadership Team with Accomplished Industry Executives - StreetInsider.com
streetinsider.com - June 15 at 7:43 AM
Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform - Seeking AlphaCellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform - Seeking Alpha
seekingalpha.com - June 15 at 7:43 AM
Cellectis Innovation Days event highlighted New Product - GlobeNewswireCellectis' Innovation Days event highlighted New Product - GlobeNewswire
globenewswire.com - June 14 at 8:02 PM
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing CapabilitiesCellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
finance.yahoo.com - June 14 at 8:02 PM
Gecina Pre-lets the Biopark Building in Paris 13th Arrondissement - StreetInsider.comGecina Pre-lets the Biopark Building in Paris' 13th Arrondissement - StreetInsider.com
streetinsider.com - June 9 at 7:53 PM
Gecina Pre-lets the Biopark Building in Paris 13th Arrondissement - Business WireGecina Pre-lets the Biopark Building in Paris' 13th Arrondissement - Business Wire
businesswire.com - June 9 at 2:53 PM
Cellectis SA Stock Gives Every Indication Of Being Possible Value Trap - Yahoo FinanceCellectis SA Stock Gives Every Indication Of Being Possible Value Trap - Yahoo Finance
finance.yahoo.com - June 5 at 9:24 AM
Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology - StreetInsider.comAllogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology - StreetInsider.com
streetinsider.com - June 4 at 1:27 PM
Cellectis SA Reports Results from Annual Shareholders - GlobeNewswireCellectis SA Reports Results from Annual Shareholders' - GlobeNewswire
globenewswire.com - June 2 at 10:04 AM
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
finance.yahoo.com - June 2 at 10:04 AM
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021 - StreetInsider.comAllogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021 - StreetInsider.com
streetinsider.com - May 19 at 7:45 PM
Global Stem Cell Therapy Market Report 2021-2030: Allogeneic Stem Cell & Therapy Autologous Stem Cell Therapy / Adult Stem Cells, Induced Pluripotent Stem Cells, & Embryonic Stem Cells - Yahoo Finance AustraliaGlobal Stem Cell Therapy Market Report 2021-2030: Allogeneic Stem Cell & Therapy Autologous Stem Cell Therapy / Adult Stem Cells, Induced Pluripotent Stem Cells, & Embryonic Stem Cells - Yahoo Finance Australia
finance.yahoo.com - May 19 at 9:26 AM
Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell - Yahoo FinanceGlobal Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell - Yahoo Finance
finance.yahoo.com - May 17 at 2:07 PM
Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences - Yahoo FinanceCytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences - Yahoo Finance
finance.yahoo.com - May 14 at 1:36 PM
Global Stem Cell Therapy Market Report 2021: COVID-19 Influences, Growth and Changes to 2030 - ResearchAndMarkets.com - Yahoo FinanceGlobal Stem Cell Therapy Market Report 2021: COVID-19 Influences, Growth and Changes to 2030 - ResearchAndMarkets.com - Yahoo Finance
finance.yahoo.com - May 14 at 8:36 AM
Allogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021 - StreetInsider.comAllogene Therapeutics to Host Virtual CD19 Forum on May 19, 2021 - StreetInsider.com
streetinsider.com - May 13 at 1:31 AM
Health Care Sector Update for 05/12/2021: INO, SIEN, CLLS, SNY, XLV, IBB - NasdaqHealth Care Sector Update for 05/12/2021: INO, SIEN, CLLS, SNY, XLV, IBB - Nasdaq
nasdaq.com - May 12 at 8:30 PM
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T - GlobeNewswireCellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T - GlobeNewswire
globenewswire.com - May 11 at 6:12 PM
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-TCellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
finance.yahoo.com - May 11 at 6:12 PM
Cellectis EPS beats by $0.52, beats on revenue - Seeking AlphaCellectis EPS beats by $0.52, beats on revenue - Seeking Alpha
seekingalpha.com - May 7 at 3:12 AM
Indias COVID-19 cases soar with over 412,000 confirmed - Yahoo Canada FinanceIndia's COVID-19 cases soar with over 412,000 confirmed - Yahoo Canada Finance
ca.finance.yahoo.com - May 6 at 5:11 PM
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021 - GlobeNewswireCellectis Provides Business Update and Reports Financial Results for First Quarter 2021 - GlobeNewswire
globenewswire.com - May 6 at 5:11 PM
This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.